First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743
| Title | First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743 |
|---|---|
| Description | Abstract publication for ESMO 2022 |
| Organism | Homo sapiens |
| Data Type | Other Type of Clinical information |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA011148 |
| Release Date | 2022-09-09 |
| Submitter | shun Lu (shunlu_shchest@sina.com) |
| Organization | Shanghai Chest Hospital |
| Submission Date | 2022-08-11 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX001599-02 | Analysis result | 1 | Other Type of Clinical information | 109.0 KB | 0 | Controlled |